EANS-Adhoc: Intercell AG announces Q2 and H1 2012 financial results and provides operational update

--------------------------------------------------------------------------------
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide
distribution. The issuer is solely responsible for the content of this
announcement.
--------------------------------------------------------------------------------

6-month report

07.08.2012

» IXIARO®/JESPECT® product sales of EUR 10.1m mark best quarterly
sales since product launch » Net profit of EUR 1.0m in Q2 - solid
execution on financial plan » Cash position strengthened through
recent financing

Vienna (Austria), August 7, 2012 - Intercell AG (VSE: ICLL)announces
Q2 and H1 2012 financial results and provides operational update.

Q2 2012 Financial Results

» Total revenues increased by 19.7% to EUR 15.2m in Q2 2012 compared
to EUR 12.7m in Q2 2011, driven by strong IXIARO®/JESPECT® sales
revenues » Strong IXIARO®/JESPECT® sales growth and reduced costs led
to a net profit of EUR 1.0m in Q2 2012, compared to a net loss of
EUR 1.6m in Q2 2011 » Total net loss in H1 2012 amounted to EUR 7.1m
- full year 2012 net loss expected towards high end of previously
communicated range of EUR 15 to 20m » Cash position of EUR 66.6m at
the end of Q2 2012, strengthened by a combined debt and equity
financing of EUR 35.2m to secure Intercell's expected funding needs
towards financial self-sustainability

Key Financial Information

EUR in thousands 3 months ended 6 months ended Year ended
June 30, June 30, June 30, June 30, Dec 31,
2012 2011 2012 2011 2011
Revenues 15,182 12,686 21,176 18,377 32,884
Net profit/(loss) 1,013 (1,608) (7,064) (12,866) (29,265)
Net operating
cash flow (480) (5,452) (9,429) (28,905) (42,858)
Cash and marketable
securities,
end of period 66,574 79,649 66,574 79,649 50,859

IXIARO®/JESPECT® product sales increased by 41.2 % to EUR 14.7m in H1 2012
compared to EUR 10.4m in H1 2011. The growth in sales was mainly driven by
increased adoption in key travel markets and supported by travel seasonality in
the second quarter, which is usually the strongest part of the year.

IXIARO®/JESPECT® is the key driver of revenue growth for Intercell and the
positive sales trend in H1 2012 underpins the growth expectations for 2012.
Intercell's partner Biological E. Ltd. is manufacturing commercial launch stock
at its facility in Hyderabad. Preparations are underway and the product launch
is imminent.

Intercell filed the submissions for approval of the IXIARO®/JESPECT® pediatric
label extension to EMA and the FDA. The pediatric approval is expected in early
2013.

Based on a positive CHMP opinion on the close-out of the EMA Article 20
procedure (Commission Regulation (EC) No 726/2004 Intercell received the formal
satisfactory close-out by the European Commission in Q2 2012.

R&D programs and activities proceeding to next stages of development

Pseudomonas aeruginosa vaccine candidate - Intercell's investigational
Pseudomonas aeruginosa vaccine is currently tested in a pivotal Phase II/III
efficacy trial. The trial follows an exploratory Phase II study in which lower
all-cause mortality rates were observed in the vaccine groups as compared to the
control group. The study enrollment is progressing and first interim data from a
futility analysis are expected in H2 2013.

Tuberculosis - In addition to the Phase II study announced in January 2012, the
Statens Serum Institut (SSI) and Intercell have initiated a second clinical
Phase II study, which assesses the safety and immunogenicity of the vaccine
candidate in healthy adolescents.

Pandemic Influenza Vaccine Enhancement Patch (VEP)- This ongoing Phase I study
investigates Intercell's adjuvant patch (Vaccine Enhancement Patch - VEP)
containing LT (a heat-labile toxin from E.coli) in combination with GSK's
H5N1-pandemic antigen. Final data are expected in H2 2012.

Pre-clinical vaccine candidate against Borrelia - The pre-clinical
lead vaccine candidate against Borrelia (Lyme Borreliosis) is heading
towards pre-clinical proof of concept by the end of this year.

Corporate/ Other

Intercell successfully completed a financing transaction consisting
of a EUR 20.0m secured loan ("Term Loan") provided by BB Biotech and
an equity private placement ("Private Placement") of approximately
EUR 15.2m. BB Biotech participated in the Private Placement with an
investment of EUR 5.0m, corresponding to a number of 2,173,913 new
shares. Intercell's biggest shareholder Novartis participated in the
equity Private Placement pro rata and maintained its 14.9% stake in
the Company.

The capital increase was completed on June 1, 2012 with the issuance
of 6,591,742 new shares and trading on the Vienna Stock Exchange. The
new shares represent 11.9% of Intercell's total share capital
following the completion of the capital increase.

The number of shares of common stock with no par value of Intercell
AG, each representing one vote, has increased to 55,183,961.

Patch vaccine collaboration with GSK

Intercell and GSK agreed in June 2012 to terminate their
collaboration on other potential patch vaccines concluded in 2009
(except the clinical trial agreement relating to the ongoing Phase I
clinical study for the VEP in Pandemic Flu). GSK agreed to make a
payment to Intercell to resolve a dispute in relation to an
outstanding milestone payment.

The report can be downloaded at http://www.intercell.com/main/forinve
stors/downloads/quarterly-reports/

Further inquiry note:
Intercell AG
Nina Waibel
Corporate Communications
Tel. +43 1 20620-1222
communications@intercell.com

end of announcement euro adhoc
--------------------------------------------------------------------------------

issuer: Intercell AG
Campus Vienna Biocenter 3
A-1030 Wien
phone: +43 1 20620-0
FAX: +43 1 20620-800
mail: investors@intercell.com
WWW: www.intercell.com
sector: Biotechnology
ISIN: AT0000612601
indexes: ATX Prime
stockmarkets: official market: Wien
language: English